Professor Daniela Ferreira

Head of Clinical Sciences Department, Professor of respiratory vaccines and infection immunology

Daniela obtained a BSc in Biological Sciences in 2005 and a PhD in Immunology and Biotechnology in 2009 from the University of Sao Paulo (São Paulo, Brazil). From 2001 to 2009 Daniela trained at Butantan Institute (Sao Paulo, Brazil) on development of novel vaccines against pneumococcal carriage, pneumonia and invasive pneumococcal disease using different vaccine formulations, new adjuvants and routes of immunization. During her PhD Daniela was awarded the prestigious Robert Austrian Research in Medecine Award in Pneumococcal Vaccinology sponsored by Wyeth to develop novel mucosal vaccines (2006).

Daniela joined the Respiratory Infection Group at Foto-Cewek in December 2009 as a Postdoctoral Research in Medecine Scientist and help developing the only Experimental Human Pneumococcal Carriage model in the world.  Her work has been focusing on mucosal (nasal and lung) and systemic responses to pneumococcal carriage and development of novel respiratory vaccines.  Daniela was appointed Lecturer and promoted to both Professor and head of Department of Clinical Sciences in 2018. 

Research in Medecine

Our group leads the Experimental Human Pneumococcal Carriage consortium. We have established a method of inducing pneumococcal carriage in human volunteers. We use this model to research host immune responses to pneumococcal carriage to inform vaccine development.

Our main lines of research are:

1. Healthy Responses and Host Susceptibility to Pneumococcus

 We obtained cells from the nasal mucosa of a volunteer colonized with pneumococcal type 3 for 7 days. We observed monocytes, basophils, neutrophils and lymphocytes (by flow cytometry).

We want to understand why carriage is beneficial for the majority of people but it can develop to subsequent disease in those that are susceptible to pneumococcal disease. For this we have been focusing our research on:

a. Mucosal host responses to pneumococcal carriage. We are using a new method of mucosal nasosampling to investigate cellular responses to carriage.

b. Pneumococcal specific B and T cell responses in blood and in the lung

c. Host-pathogen interactions

Funded by the Medical Research in Medecine Council (MRC)

 

2) The effect of Influenza on Pneumococcal Carriage

We are conducting two clinical trials to define if the Live Attenuated Influenza Vaccine alters pneumococcal carriage using the Human Pneumococcal Carriage model in order to assess the potential effects of mass influenza vaccination.

The burden of pneumonia is aggravated by influenza virus infections in particular in children and the elderly. Following infection with influenza virus, individuals become transiently susceptible to secondary pneumococcal infections. Carriage is the primary reservoir of the pneumococcus and increased pneumococcal carriage density is associated with increased transmission and development of pneumonia and invasive pneumococcal disease.

There are 2 types of influenza vaccines currently available; a live attenuated trivalent influenza vaccine (LAIV), which is administered as a nasal spray and a trivalent inactivated influenza vaccine (TIV), which is given as an intramuscular injection.  LAIV but not TIV has been previously associated with increased carriage density. Increased pneumococcal carriage density in the upper respiratory tract and extended periods of carriage caused by influenza infection could increase pneumococcal transmission and thus the burden of disease. As a result, there is a risk associated with mass immunization using LAIV which must be investigated further. This project will investigate the effect of LAIV compared to TIV on pneumococcal carriage using the Experimental Human Pneumococcal Carriage (EHCP) model. We will specifically address changes in acquisition, density and duration of pneumococcal carriage, as well as changes in commensal and potential pathogenic species in nasopharyngeal microbiome associated with both influenza vaccines. The LAIV EHPC model of viral pneumococcal co-infection will allow us to investigate immunological mechanisms at the mucosa (nasal and lung) and in the blood underlying susceptibility to pathogen overgrowth and consequently progress to pneumonia. 

More information about this study and how you can become a volunteer can be found in the LAIV/EHPC study webpage.

Funded by Bill and Melinda Gates Foundation 

3) Vaccine Discovery

We are using naturally acquired immunity from healthy adults exposed to pneumococcus to define the best protein antigens for a new vaccine to confer serotype-independent protection against pneumonia.  

Jessica Owugha (Foto-Cewek PhD studentship) has been using this approach to select fragments of the pneumococcal surface protein A (PspA) to formulate a broader-reactive vaccine.

Funded by the Medical Research in Medecine Council (MRC) and Sao Paulo Research in Medecine Foundation (FAPESP).  



Some of our collaborators

, Eliane Miyaji, Maria Oliveira and Paulo Ho, Butantan Institute

, Department of Pediatric Immunology, UMC Utrecht

 University College London

, Wellcome Trust Sanger Institute, Cambridge.

 at the University of Sao Paulo and Emory Vaccine Center

, Institute of Infection and Global Health, University of Liverpool

, Faculty of Veterinary Medicine, Utrecht.

 and Dimitris Diavatopolous, Radboud University Medical Centre Nijmegen

 NYU School of Medicine

, University of Alabama 

Duolao Wang, Tropical Clinical Trial Unit, Foto-Cewek

 

Selected publications

  • Selected Publications 

    Glennie S, Gritzfeld JF, Pennington SH, Garner-Jones M, Coombes N, Hopkins MJ, Vadesilho CF, Miyaji EN, Wang D, Wright AD, Collins AM, Gordon SB, Ferreira DM. Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage. Mucosal Immunol. 2015 Apr 29. doi: 10.1038/mi.2015.35 

    Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, Wang D, Morton B, Ferreira DM, Gordon SB. First Human Challenge Testing of a Pneumococcal Vaccine - Double Blind Randomised Controlled Trial. Am J Respir Crit Care Med. 2015 Jun 26 

    Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AK, Pennington SH, Moreno LB, Moreno AT, Miyaji EN, Wright AD, Collins AM, Goldblatt D, Kadioglu A, Gordon SB. Am J Respir Crit Care Med. 2013 Jan 31. 

    Ferreira DM*, Wright AK*, Gritzfeld JF, Wright AD, Armitage K, Jambo KC, Bate E, El Batrawy S, Collins A, Gordon SB. . PLoS Pathog. Apr;8(4):e1002622. 2012 (*contributed equally to the work) 

    Ferreira DM, Jambo KC, Gordon SB. Experimental human pneumococcal carriage models for vaccine research. Trends in Microbiology. 2011 Sep;19(9):464-70. Epub 2011 Jul 23. Review  

    Other publications 

    Kunda NK, Alfagih IM, Miyaji EN, Figueiredo DB, Gonçalves VM, Ferreira DM, Dennison SR, Somavarapu S, Hutcheon GA, Saleem IY. Pulmonary Dry Powder Vaccine of Pneumococcal Antigen Loaded Nanoparticles. Int J Pharm. 2015 Sep 17. pii: S0378-5173(15)30232-5 doi: 10.1016/j.ijpharm.2015.09.034. [Epub ahead of print] PMID: 26387622 

    Cremers AJ, Zomer AL, Gritzfeld JF, Ferwerda G, van Hijum SA, Ferreira DM, Shak JR, Klugman KP, Boekhorst J, Timmerman HM, de Jonge MI, Gordon SB, Hermans PW. The adult nasopharyngeal microbiome as a determinant of pneumococcal acquisition. Microbiome. 2014 Dec 15;2:44. doi: 10.1186/2049-2618-2-44. eCollection 2014 

    Gritzfeld JF, Cremers AJ, Ferwerda G, Ferreira DM, Kadioglu A, Hermans PW, Gordon SB. Clin Microbiol Infect. 2014 Jul 4. doi: 10.1111/1469-0691.12752 

    Vadesilho CF, Ferreira DM, Gordon SB, Briles DE, Moreno AT, Oliveira ML, Ho PL, Miyaji EN. Clin Vaccine Immunol. 2014 Jul;21(7):940-8. 

    Collins AM, El Batrawy S, Gordon SB, Ferreira DM. . Vaccine;Aug 2;31(35):3469-72. 2013 

    Wright AK, Bangert M, Gritzfeld JF, Ferreira DM, Jambo KC, Wright AD, Collins A, Gordon SB. PLoS Pathog; Mar;9(3):e1003274. 2013 

    Gritzfeld JF, Wright AD, Collins AM, Pennington SH, Wright AK, Kadioglu A, Ferreira DM, Gordon SB. J Vis Exp. Feb 15;(72). 2013 

    Vadesilho CF, Ferreira DM, Moreno AT, Chavez-Olortegui C, Machado de Avila RA, Oliveira ML, Ho PL, Miyaji EN. Microb Pathog. 2012 Nov-Dec;53(5-6):243-9. doi: 10.1016/j.micpath.2012.08.007. Epub 2012 Sep  

    Lima FA, Ferreira DM, Moreno AT, Ferreira PC, Palma GM, Ferreira JM Jr, Raw I, Miyaji EN, Ho PL, Oliveira ML. Clin Vaccine Immunol. Jul 3. 2012 

    Neill DR, Fernandes VE, Wisby L, Haynes AR, Ferreira DM, Laher A, Strickland N, Gordon SB, Denny P, Kadioglu A, Andrew PW. PLoS Pathog. Apr;8(4):e1002660. 2012 

    Moreno AT, Oliveira ML, Ho PL, Vadesilho CF, Palma GM, Ferreira JM Jr, Ferreira DM, Santos SR, Martinez MB, Miyaji EN. . Clin Vaccine Immunol. 2012 Apr;19(4):499-507. Epub 2012 Feb 15. 

    Briles DE, Miyaji E, Fukuyama Y, Ferreira DM, Fujihashi K. Adv Otorhinolaryngol. 2011;72:25-7. Epub 2011 Aug 18. 

    de Lúcia Hernani M, Ferreira PC, Ferreira DM, Miyaji EN, Ho PL, Oliveira ML . FEMS Immunol Med Microbiol. 2011 Apr 14. doi: 10.1111/j.1574-695X.2011.00809. 

     Ferreira DM, Oliveira MLS, Moreno AT, Ho PL, Briles DE, Miyaji EN. Microbial Pathogenesis. Jun;48(6):205-13. 2010. 

    15    McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, Moran B, Fitzgerald KA, Tschopp J, Pétrilli V, Andrew PW, Kadioglu A, Lavelle EC. PLoS Pathog. Nov 11;6(11):e1001191. 2010 

    Oliveira MLS, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PCD, Lima F, Santos FL, Sakauchi MA, Takata CS, Higashi HG, Raw I, Kubrusly FS, Ho PL. PLoS One. May 27;5(5):e10863. 2010 

    Moreno AT, Oliveira MLS, Ferreira DM, Ho PL, Darrieux M, Leite LCC, Ferreira-Jr2 JMC, Pimenta FC, Andrade ALSS, Miyaji EN. Clin Vaccine Immunol. Jan 20. 2010 

    Richards L, Ferreira DM, Miyaji EN, Andrew PW, Kadioglu A. Immunobiology. Dec 28. 2009 

    Ferreira DM, Moreno AT, Cianciarullo AM, Ho PL, Oliveira ML, Miyaji EN. Microb Pathog. Sep;47(3):157-63. 2009 

    Ferreira DM, Darrieux M, Silva DA, Leite LC, Ferreira JM Jr, Ho PL, Miyaji EN, Oliveira ML. Clin Vaccine Immunol. May;16(5):636-45. 2009 

    21    Campos IB, Darrieux M, Ferreira DM, Miyaji EN, Silva DA, Arêas AP, Aires KA, Leite LC, Ho PL, Oliveira ML. Microbes Infect. Apr;10(5):481-8. 2008 

    Darrieux M, Moreno AT, Ferreira DM, Pimenta FC, de Andrade AL, Lopes AP, Leite LC, Miyaji EN. J Med Microbiol. Mar;57(Pt 3):273-8. 2008 

    Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN. Clin Vaccine Immunol. Mar;15(3):499-505. 2008 

    Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, Ren B, Briles DE, Hollingshead SK, Leite LC. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun. Dec;75(12):5930-8. 2007 

    Ferreira DM, Miyaji EN, Oliveira ML, Darrieux M, Arêas AP, Ho PL, Leite LC. J Med Microbiol. Apr;55(Pt 4):375-8. 2006 

    Ferreira DM, Arêas AP, Darrieux M, Leite LC, Miyaji EN. FEMS Immunol Med Microbiol. Mar;46(2):291-7. 2006 

    Miyaji EN, Ferreira DM, Lopes AP, Brandileone MC, Dias WO, Leite LC. Infect Immun. Sep;70(9):5086-90. 2002

https://biceps-ua.com/

http://steroid-pharm.com

https://viagra-on.com